Datroway datopotamab deruxtecan

Drug Class

TROP2-directed antibody-drug conjugate (ADC)

Mechanism

Binds to TROP2 on tumor cells and internalizes, releasing a cytotoxic topoisomerase I inhibitor payload to induce DNA damage and cell death.

Approved Indication

FDA-approved for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

What This Means For Patients

Datroway is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2026) — Sources

Pivotal Clinical Evidence

• TROPION-Breast02 — Bardia et al., Ann Oncol 2026 (NCT05374512) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-approvals-and-safety-notifications
• https://www.astrazeneca.com/media-centre/press-releases.html